Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Eur Rev Med Pharmacol Sci ; 26(24): 9230-9239, 2022 12.
Article in English | MEDLINE | ID: mdl-36591835

ABSTRACT

OBJECTIVE: Serum ACE2 level in the acute phase of ST-segment elevation myocardial infarction may be an indicator of heart failure, however, limited studies have reported conflicting results. Therefore, in our study, we aimed to evaluate the relationship between serum ACE2 level and infarct size in the acute phase of ST-segment elevation myocardial infarction and compare the predictive value of ACE2 level with classical biomarkers. PATIENTS AND METHODS: Sixty-six patients after the primary percutaneous coronary intervention were included in the study. For the measurement of serum ACE2 levels, blood samples were taken twice from the patients: in the first 24 hours and on the 5th day of the infarction, and once from 30 healthy volunteers. hs-cTnT, BNP, and CRP levels were measured daily, and their peak values were taken. On the 7th day of ST-segment elevation myocardial infarction, gSPECT was used with the 99mTc-MIBI method for assessment of infarct size. RESULTS: Baseline ACE2 values were found to be higher in patients compared to controls, and ACE2 values obtained on the 5th day were found to be higher than the baseline values in the patients. There was no significant correlation between serum ACE2 levels and the RSS (%), while peak levels of hs-cTnT, BNP, and CRP were assessed as predictive factors for the RSS (%). CONCLUSIONS: Although serum ACE2 levels increased in the acute phase of ST-segment elevation myocardial infarction, this increase was not associated with infarct size. Serum ACE2 level did not provide additional benefit to classical biomarkers for infarct size-related prognosis prediction.


Subject(s)
Angiotensin-Converting Enzyme 2 , ST Elevation Myocardial Infarction , Humans , Angiotensin-Converting Enzyme 2/blood , Angiotensin-Converting Enzyme 2/metabolism , Biomarkers/blood , Biomarkers/metabolism , Percutaneous Coronary Intervention , Prognosis , ST Elevation Myocardial Infarction/blood , ST Elevation Myocardial Infarction/diagnosis , ST Elevation Myocardial Infarction/metabolism , ST Elevation Myocardial Infarction/therapy , Treatment Outcome
2.
Acta Endocrinol (Buchar) ; 13(1): 84-89, 2017.
Article in English | MEDLINE | ID: mdl-31149153

ABSTRACT

The effects of finasteride on insulin resistance and of metformin on hyperandrogenism in patients with polycystic ovary syndrome (PCOS) are not clear. This study therefore compared the effects of finasteride, metformin, and finasteride plus metformin treatments on hormone levels, insulin resistance, and hirsutism score in women with PCOS. Fifty-two patients with PCOS were randomly assigned to receive finasteride 5 mg/day, metformin 1700 mg/day or finasteride plus metformin for 12 months. Body mass index (BMI), Ferriman Gallway score (FGS), serum concentrations of estradiol, sex hormone-binding globulin, free testosterone, dehydroepiandrosterone sulfate (DHEAS), androstenedione, and homeostasis model assessment of insulin resistance (HOMA-IR) index and areas under the curve (AUC) for insulin and glucose were evaluated before and after 12 months of treatment. Reductions in FGS, free testosterone, DHEAS, androstenedione, HOMA-IR, AUC-insulin, and AUC-glucose were significant within each group, whereas BMI and estradiol were not. Comparisons of changes in parameters in the 3 groups did not clearly show the superiority of any treatment modality. The treatment with finasteride alone significantly reduced both androgen levels and parameters of insulin resistance. In addition, metformin alone was effective, and not inferior to finasteride, in the treatment of hyperandrogenism.

3.
J Food Sci ; 72(1): S049-54, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17995897

ABSTRACT

We formulated a filling for sandwich cookies containing 400 mg of eicosapentaenoic acid, 20:5, n-3 (EPA) + docosahexaenoic acid, 22:6, n-3 (DHA) encapsulated in a matrix of starch and gelatin. Cookies were stored at 2 different temperatures (18 degrees C and 35 degrees C) and under 2 different packaging conditions (atmospheric and vacuum packed) for 28 d. At regular intervals, cookies were analyzed for moisture, water activity, and concentrations of EPA, DHA, and dienes. Results showed that there were no significant losses of EPA and DHA during storage under the conditions of study. A maximum loss of 5% was observed after 28 d of storage. The concentration of dienes obtained under different conditions were low (< 25 mmol/kg) as compared to a salmon oil sample with appreciable signs of oxidation (600 mmol/kg). Sensory evaluation of cookies by an untrained panel of healthy consumers and ulcerative colitis patients revealed no aftertaste and high acceptability of the cookies. Our results demonstrated that it is possible to make shelf-stable fortified foods with high levels of long-chain omega3FA.


Subject(s)
Fatty Acids, Omega-3/analysis , Food Packaging/methods , Food, Fortified , Food, Organic , Consumer Behavior , Docosahexaenoic Acids/administration & dosage , Docosahexaenoic Acids/analysis , Docosahexaenoic Acids/chemistry , Eicosapentaenoic Acid/administration & dosage , Eicosapentaenoic Acid/analysis , Eicosapentaenoic Acid/chemistry , Fatty Acids, Omega-3/administration & dosage , Fatty Acids, Omega-3/chemistry , Humans , Oxidation-Reduction , Taste , Temperature , Time Factors , Water/metabolism
4.
Exp Clin Endocrinol Diabetes ; 115(8): 522-6, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17853336

ABSTRACT

The present study was designed to investigate the relationship between the serum levels of oxidant-antioxidant system (malondialdehyde (MDA) level, Paraoxonase (PON1) activity, nitric oxide (NO) level and superoxide dismutase (SOD) activity) and thyroid hormone status in hypothyroidism pre and posttreatment. The study group comprised 33 patients with primary hypothyroidism. 18 of these patients were reevaluated after euthyroid state i.e. at least 6 months of thyroxine replacement. The patients were compared with 26 normal healthy controls. Serum MDA level, PON1 activity, NO level and SOD activity were measured according to an enzymatic spectrophotometric method. MDA levels were found higher in patients with hypothyroidism before the treatment than the controls. MDA levels were also found to be decreased after the treatment in patients with hypothyroidism. However MDA were found still higher than the controls after the treatment. PON1 activity was found to be lower in patients pretreatment when compared to posttreatment hypothyroidism and controls. Posttreatment of hypothyroidism mean PON1 activity significantly increased compared to pretreatment level but it was still significantly lower than control level. NO level was higher in pretreatment hypothyroidism when compared to controls. SOD activity was not found different in patients before treatment when compared to controls. SOD activity was significantly higher in after treatment when compared to both pretreatment and control levels. In conclusion, increased ROS levels in hypothyroidism may result in a pro-oxidation environment, which in turn could result in decreased antioxidant PON1 activity, increased MDA and NO levels. As a result, lipid peroxidation may have a role in the pathogenesis of the atherosclerosis in hypothyroidism.


Subject(s)
Antioxidants/metabolism , Aryldialkylphosphatase/blood , Hypothyroidism/blood , Hypothyroidism/drug therapy , Malondialdehyde/blood , Oxidative Stress , Adult , Aged , Female , Hashimoto Disease/blood , Hashimoto Disease/drug therapy , Humans , Male , Middle Aged , Nitric Oxide/blood , Superoxide Dismutase/blood , Thyroxine/blood , Thyroxine/therapeutic use , Triiodothyronine/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...